These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2767112)

  • 1. Mitozolomide in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
    van Oosterom AT; Stoter G; Bono AV; Splinter TA; Fossa SD; Verbaeys AJ; de Mulder PH; de Pauw M; Sylvester R
    Eur J Cancer Clin Oncol; 1989 Aug; 25(8):1249-50. PubMed ID: 2767112
    [No Abstract]   [Full Text] [Related]  

  • 2. TCNU in advanced renal cancer. Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
    Van Oosterom AT; Droz JP; Fossa ST; Bono AV; Splinter TA; Verbaeys AJ; Keizer J; De Pauw M; Sylvester R
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1889-90. PubMed ID: 2632270
    [No Abstract]   [Full Text] [Related]  

  • 3. Mitoxantrone in advanced renal cancer: a phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
    van Oosterom AT; Fosså SD; Pizzocaro G; Bergerat JP; Bono AV; De Pauw M; Sylvester R
    Eur J Cancer Clin Oncol; 1984 Oct; 20(10):1239-41. PubMed ID: 6541582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of mitozolomide in patients with advanced ovarian cancer. A study of the EORTC Gynecological Cancer Cooperative Group.
    Neijt JP; van der Burg ME; Guastalla JP; George M; Piccart M; Vermorken J; Carnino F; Rotmensz N
    Acta Oncol; 1989; 28(5):663-5. PubMed ID: 2590542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group.
    Somers R; Santoro A; Verweij J; Lucas P; Rouëssé J; Kok T; Casali A; Seynaeve C; Thomas D
    Eur J Cancer; 1992; 28A(4-5):855-7. PubMed ID: 1524907
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma. EORTC Early Clinical Trials Group.
    Smyth JF; Gundersen S; Renard J; Pinedo HM
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):755-7. PubMed ID: 2714350
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II study of mitozolomide (M & B 39,565) in head and neck cancer.
    Herait P; Armand JP; Benahmed M; Domenge C; Fontana X; Recondo G; Cvitkovic E; Delgado FM
    Med Oncol Tumor Pharmacother; 1989; 6(4):267-9. PubMed ID: 2615530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of mitozolomide in metastatic transitional cell carcinoma of the bladder.
    Blackledge G; Roberts JT; Kaye S; Taylor R; Williams J; de Stavola B; Uscinska B
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):391-2. PubMed ID: 2702992
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II evaluation of mitozolomide in ovarian cancer.
    Harding M; Northcott D; Smyth J; Stuart NS; Green JA; Newlands E
    Br J Cancer; 1988 Jan; 57(1):113-4. PubMed ID: 3348943
    [No Abstract]   [Full Text] [Related]  

  • 10. Abbreviated phase I clinical trial of i.v. mitozolomide.
    Joss RA; Ryssel HJ; Bischoff AK; Goldhirsch A; Brunner KW
    Cancer Treat Rep; 1986 Jun; 70(6):797-8. PubMed ID: 3524827
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer.
    Herait P; Rougier P; Oliveira J; Delgado FM; May-Levin F; Hayat M; Armand JP
    Invest New Drugs; 1988 Dec; 6(4):323-5. PubMed ID: 3229944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II studies of mitozolomide in melanoma, lung and ovarian cancer.
    Harding M; Docherty V; Mackie R; Dorward A; Kaye S
    Eur J Cancer Clin Oncol; 1989 May; 25(5):785-8. PubMed ID: 2544429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4'Deoxydoxorubicin in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
    van Oosterom AT; Bono AV; Kaye SB; Splinter TA; Calciati A; Fosså SD; de Pauw M; Sylvester R
    Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1531-2. PubMed ID: 3595678
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group Trial.
    Gams RA; Nelson O; Birch R
    Cancer Treat Rep; 1986 Jul; 70(7):921-2. PubMed ID: 3521848
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I study of mitozolomide on a once daily for 5 days schedule.
    Schornagel JH; Simonetti G; Dubbelman R; ten Bokkel Huinink WW; McVie JG
    Cancer Chemother Pharmacol; 1990; 26(3):237-8. PubMed ID: 2357772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of N-methylformamide for advanced renal cell carcinoma.
    Sternberg CN; Yagoda A; Scher HI; Hollander P
    Cancer Treat Rep; 1986 May; 70(5):681-2. PubMed ID: 3708620
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I clinical trial of mitozolomide.
    Newlands ES; Blackledge G; Slack JA; Goddard C; Brindley CJ; Holden L; Stevens MF
    Cancer Treat Rep; 1985; 69(7-8):801-5. PubMed ID: 4016790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease.
    Gundersen S; Aamdal S; Fodstad O
    Br J Cancer; 1987 Apr; 55(4):433-5. PubMed ID: 3580266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of elliptinium in advanced renal cell carcinoma.
    Caillé P; Mondesir JM; Droz JP; Kerbrat P; Goodman A; Ducret JP; Theodore C; Spielman M; Rouëssé J; Amiel JL
    Cancer Treat Rep; 1985; 69(7-8):901-2. PubMed ID: 4016798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study with a new alkylating agent (PTT-119) in lymphoid malignancies.
    Tura S; Mazza P; Gherlinzoni F; Zinzani PL; Poletti G; Visani G; Lemoli RM; Bandini G; Cavo M; Galieni P
    Haematologica; 1988; 73(6):503-8. PubMed ID: 3148513
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.